Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402363 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
A Phase 3 study of Fibrillation, Atrial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 663
- Enrollment target
- 20
- Study locations
NCT00402363 is a Phase 3 study of Fibrillation, Atrial that has completed, run by GlaxoSmithKline. The registered enrollment target is 663 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT00402363, a Phase 3 study of Fibrillation, Atrial, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 663 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG omega-3-acid ethyl esters
Study Locations (20)
California
- GSK Investigational Site - Alamada
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Bakersfield
- GSK Investigational Site - Beverly Hills
- GSK Investigational Site - Carmichael
- GSK Investigational Site - Fair Oaks
- GSK Investigational Site - Fountain Valley
- GSK Investigational Site - Loma Linda
- GSK Investigational Site - Los Angeles
Arizona
- GSK Investigational Site - Cottonwood
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Huntsville
Arkansas
- GSK Investigational Site - Fort Smith
- GSK Investigational Site - Hot Springs
Alaska
- GSK Investigational Site - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 663 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402363
The ClinicalTrials.gov registry entry for NCT00402363 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 663 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrillation, Atrial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00402363 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00402363 about?
NCT00402363 is a clinical study titled "Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation". The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
What is the current status of trial NCT00402363?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 663 participants. The study started on 2006-11. Estimated completion is 2010-01.
What conditions does trial NCT00402363 study?
This clinical trial studies the following conditions: Fibrillation, Atrial.
What interventions are being tested in trial NCT00402363?
The interventions under investigation include: Placebo (DRUG), omega-3-acid ethyl esters (DRUG).
Who is sponsoring clinical trial NCT00402363?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00402363 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.